EFM
SGMO

E Fund Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

E Fund Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-24,853
Closed -$25.4K – 424
2024
Q4 		$25.4K Buy
+24,853
New +$45.4K ﹤0.01% 393
2023
Q2 		– Sell
-35,003
Closed -$62K – 334
2023
Q1 		$62K Sell
35,003
-2,004
-5% -$5.72K ﹤0.01% 330
2022
Q4 		$116K Buy
37,007
+9,284
+33% +$36K 0.01% 324
2022
Q3 		$136K Sell
27,723
-3,869
-12% -$19.9K 0.01% 321
2022
Q2 		$131K Buy
31,592
+8,491
+37% +$36.7K 0.01% 315
2022
Q1 		$134K Buy
23,101
+11,383
+97% +$67.7K ﹤0.01% 311
2021
Q4 		$88K Buy
11,718
+672
+6% +$5.84K ﹤0.01% 291
2021
Q3 		$100K Buy
+11,046
New +$109K ﹤0.01% 259
2021
Q1 		$151K Buy
+12,015
New +$162K 0.01% 222

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

E Fund Management's SGMO Position: Q1 2025 in Review

E Fund Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2025, closing a stake of 24,853 shares — an estimated $25.4K sold.

E Fund Management first reported a position in SGMO in Q1 2021 and held it in 9 quarters. The position peaked at $151K in Q1 2021. 122 funds tracked by Wall St. Rank hold SGMO as of Q1 2025.

  • E Fund Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2025 after selling out during the quarter.
  • E Fund Management sold 24,853 SANGAMO THERAPEUTICS INC shares in Q1 2025, an estimated $25.4K.
  • E Fund Management first reported a position in SANGAMO THERAPEUTICS INC in Q1 2021 and held it in 9 quarters.
  • E Fund Management's SANGAMO THERAPEUTICS INC position peaked at $151K in Q1 2021.
  • 122 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2025.

Based on E Fund Management's 13F filing for Q1 2025, filed 13 May 2025.